Douglas Sawyer
Faculty Member
Last active: 7/21/2014

Galectin 3 complements BNP in risk stratification in acute heart failure.

Fermann GJ, Lindsell CJ, Storrow AB, Hart K, Sperling M, Roll S, Weintraub NL, Miller KF, Maron DJ, Naftilan AJ, McPherson JA, Sawyer DB, Christenson R, Collins SP
Biomarkers. 2012 17 (8): 706-13

PMID: 22998064 · PMCID: PMC3678263 · DOI:10.3109/1354750X.2012.719037

BACKGROUND - Galectin 3 (G3) is a mediator of fibrosis and remodeling in heart failure.

METHODS - Patients diagnosed with and treated for Acute Heart Failure Syndromes were prospectively enrolled in the Decision Making in Acute Decompensated Heart Failure multicenter trial.

RESULTS - Patients with a higher G3 had a history of renal disease, a lower heart rate and acute kidney injury. They also tended to have a history of HF and 30-day adverse events compared with B-type natriuretic peptide.

CONCLUSION - In Acute Heart Failure Syndromes, G3 levels do not provide prognostic value, but when used complementary to B-type natriuretic peptide, G3 is associated with renal dysfunction and may predict 30-day events.

MeSH Terms (18)

Acute Disease Adult Aged Aged, 80 and over Biomarkers Female Galectin 3 Heart Failure Humans Male Middle Aged Natriuretic Peptide, Brain Outcome Assessment, Health Care Prognosis Prospective Studies Risk Assessment Risk Factors Syndrome

Connections (1)

This publication is referenced by other Labnodes entities: